Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | FSHR | P23945 | 15/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192676 | 0.86 | TSHR (0.64) | TSHRFSHR | |
| SCHEMBL3526145 | 0.86 | TSHR (0.46) | TSHRFSHREPHX2KMT2A | |
| SCHEMBL3521654 | 0.85 | TSHR (0.46) | TSHRFSHREPHX2KMT2A | |
| SCHEMBL2189826 | 0.84 | FSHR (0.64) | TSHRFSHRKMT2A | |
| SCHEMBL2195585 | 0.83 | TSHR (0.44) | TSHRFSHREPHX2KMT2A | |
| SCHEMBL2194165 | 0.81 | TSHR (0.65) | TSHRFSHR | |
| SCHEMBL3655121 | 0.80 | FSHR (0.62) | TSHRFSHR | |
| SCHEMBL3396086 | 0.79 | FSHR (0.60) | TSHRFSHREPHX2KMT2A | |
| SCHEMBL2196163 | 0.78 | TSHR (0.61) | TSHRFSHR | |
| SCHEMBL2194212 | 0.78 | TSHR (0.61) | TSHRFSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197445-B1 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2017-04-19 | — | — | EP | disclosed |
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | disclosed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | disclosed |
| US-7858794-B2 | Tetrahydroquinoline derivatives | N.V. ORGANON (NL) | 2010-12-28 | — | — | US | disclosed |
| EP-1578726-B1 | TETRAHYDROQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-02-25 | — | — | EP | disclosed |
| US-20060142334-A1 | Tetrahydroquinoline derivatives | MERCK SHARP & DOHME B.V. (NL) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142334-A1 | Tetrahydroquinoline derivatives | GNRHR, KCNH3, HCAR3 | TSHR 628/4885FSHR 9/4885EPHX2 1893/4885 |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | TSHR, MC1R, TRHR | TSHR 1/4885FSHR 21/4885EPHX2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.